-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atopic dermatitis (AD) severely affects the patient's quality of life (QoL).
The researchers analyzed the aggregated data of two phase 3 studies of the same design, LIBERTY AD SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), and assessed the following PROs: Numerical Rating Scale for Pruritus (NRS), Pruritus Classification Scale, SCORing AD (SCORAD), Dermatological Quality of Life Index (DLQI), Patient-Oriented Eczema Measurement (POEM), Hospital Anxiety and Depression Scale (HADS), Five-Dimension European Quality of Life Questionnaire (EQ-5D), and patient assessment Disease conditions and treatment effects.
The results showed that compared with placebo, dupilumab quickly improved the Peak Pruritus NRS score (p <.
In summary, the results of the study show that Dupilumab significantly improves AD symptoms, including itching, sleep, pain, anxiety and depression, and QoL in adults with moderate to severe AD.
Original source:
Michael J Cork, et al.
ncbi.
nlm.
nih.
gov/31179791/" target="_blank" rel="noopener">Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
in this message